GeoVax Starts Phase 3 Immunobridging Trial with 500 Participants, 8-12 Week Readout
GeoVax has initiated Phase 3 immunobridging clinical study execution for GEO-MVA, enrolling 500 participants under EMA guidance with results expected within 8-12 weeks. The study compares neutralizing antibody responses against an approved MVA vaccine to support potential regulatory authorization and commercialization.
1. Phase 3 Program Initiation
GeoVax has launched operational execution activities for its pivotal Phase 3 immunobridging study of GEO-MVA, marking a shift from planning to active trial setup and site engagements aimed at accelerating clinical validation.
2. Trial Design and Timeline
The planned arm will enroll approximately 500 participants to evaluate neutralizing antibody responses relative to an approved MVA-based comparator, with immunobridging data anticipated 8–12 weeks after trial commencement.
3. Regulatory Pathway
The study is structured under EMA-aligned scientific advice to leverage an expedited immunobridging pathway, potentially enabling regulatory submission based on non-inferiority data rather than traditional efficacy endpoints.
4. Commercial Strategy and Global Need
GEO-MVA is positioned as a second-source MVA vaccine for mpox and smallpox to bolster global supply resilience, addressing ongoing public health and biodefense preparedness requirements.